// App-Quantinova.ai

OT1-2-02 : Trastuzumab in HER2-negative early breast cancer as adjuvant treatment for circulating tumor cells (CTCs) (Treat CTC)

Researchers

Presenter

  • Ignatiadis M

Principal Investigators

  • Messina C

  • Litiere SMavroudis DDittrich C

  • Kong A

  • Janni W

  • Sotiriou C

  • Piccart M

  • Pierga J-Y

  • Rack B

Medical Centers

  • Institut Curie, France

  • LBI-ACR VIEnna LBC-TO, Kaiser Franz Josef-Spital, AustriaLudwig-Maximilians-University, Munich, Germanyan Organization for Research and Treatment of Cancer (EORTC), Belgium

  • Universitatsklinikum Ulm, Ulm, Germany

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

  • Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, United Kingdom

  • University Hospital of Heraklion, Crete, Greece

Locations

  • Greece

  • Germany

  • United Kingdom

  • France

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

Outcome

  • N/A

Study Design

  • superiority

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved